<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<style>body{background-color:white;}</style>


</head>
<body>
<style>html {
  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;
}

#thhpfjzghv .gt_table {
  display: table;
  border-collapse: collapse;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 16px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#thhpfjzghv .gt_heading {
  background-color: #FFFFFF;
  text-align: center;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#thhpfjzghv .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#thhpfjzghv .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 0;
  padding-bottom: 4px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#thhpfjzghv .gt_bottom_border {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#thhpfjzghv .gt_col_headings {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#thhpfjzghv .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#thhpfjzghv .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#thhpfjzghv .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#thhpfjzghv .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#thhpfjzghv .gt_column_spanner {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#thhpfjzghv .gt_group_heading {
  padding: 8px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
}

#thhpfjzghv .gt_empty_group_heading {
  padding: 0.5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#thhpfjzghv .gt_from_md > :first-child {
  margin-top: 0;
}

#thhpfjzghv .gt_from_md > :last-child {
  margin-bottom: 0;
}

#thhpfjzghv .gt_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#thhpfjzghv .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 12px;
}

#thhpfjzghv .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#thhpfjzghv .gt_first_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
}

#thhpfjzghv .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#thhpfjzghv .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#thhpfjzghv .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#thhpfjzghv .gt_table_body {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#thhpfjzghv .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#thhpfjzghv .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding: 4px;
}

#thhpfjzghv .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#thhpfjzghv .gt_sourcenote {
  font-size: 90%;
  padding: 4px;
}

#thhpfjzghv .gt_left {
  text-align: left;
}

#thhpfjzghv .gt_center {
  text-align: center;
}

#thhpfjzghv .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#thhpfjzghv .gt_font_normal {
  font-weight: normal;
}

#thhpfjzghv .gt_font_bold {
  font-weight: bold;
}

#thhpfjzghv .gt_font_italic {
  font-style: italic;
}

#thhpfjzghv .gt_super {
  font-size: 65%;
}

#thhpfjzghv .gt_footnote_marks {
  font-style: italic;
  font-size: 65%;
}
</style>
<div id="thhpfjzghv" style="overflow-x:auto;overflow-y:auto;width:auto;height:auto;"><table class="gt_table">
  <thead class="gt_header">
    <tr>
      <th colspan="8" class="gt_heading gt_title gt_font_normal" style>Appendix IV: Key results of included articles</th>
    </tr>
    <tr>
      <th colspan="8" class="gt_heading gt_subtitle gt_font_normal gt_bottom_border" style></th>
    </tr>
  </thead>
  <thead class="gt_col_headings">
    <tr>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1">Author (year)</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1">ICER</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1">Currency (year)</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1">Inclusion of stochasticity</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1">Reporting of uncertainty</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1">Main findings</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1">Cost-effectiveness verdict</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1">CHEERS score</th>
    </tr>
  </thead>
  <tbody class="gt_table_body">
    <tr class="gt_group_heading_row">
      <td colspan="8" class="gt_group_heading">Trial-based analyses</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Bogdanova (2019)</td>
      <td class="gt_row gt_left">SSm+ LPA-based diagnostics reducuded the costs by 4.5 compared to LJ and by 2.5 times compared to BacTAlert liquid culture</td>
      <td class="gt_row gt_left">US dollars (2014)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA</td>
      <td class="gt_row gt_left">TB diagnostic algorithms incorporating LPA method proved to be both more clinically effective and less expensive due to reduction in the number of hospital days to the correct MDR-TB diagnosis and treatment initiation</td>
      <td class="gt_row gt_left">Cost-saving</td>
      <td class="gt_row gt_left">15</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Böhmer (2002)</td>
      <td class="gt_row gt_left">No incremental cost-effectiveness outcomes reported, only individual costs (microbiology: -11.77; imaging procedures: 8.32; antibiotic costs: -114.04; application costs: -100.41) and individual effects (application time (h): -5.4; days with symptoms: -3.5; days with antibiotics: -3; hospital length-of-stay (days): -3)</td>
      <td class="gt_row gt_left">Not reported</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA</td>
      <td class="gt_row gt_left">Improvements were found for the patients (fewer infusions, faster symptom resolution and a shorted length-of-stay)</td>
      <td class="gt_row gt_left">Cost-saving</td>
      <td class="gt_row gt_left">11</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Dinh (2018)</td>
      <td class="gt_row gt_left">As only 7 PUA tests led to appropriate antimicrobial modification, we deemed that the potential cost savings, if the test had not been used, would have been 26,244 € during 3 years, that is 8748 € per year.</td>
      <td class="gt_row gt_left">Not reported</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA</td>
      <td class="gt_row gt_left">The test should be used only for patients with probable CAP</td>
      <td class="gt_row gt_left">Cost-saving</td>
      <td class="gt_row gt_left">13</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Nicholson (2014)</td>
      <td class="gt_row gt_left">734717 per QALY</td>
      <td class="gt_row gt_left">Pound Sterling (2007)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA, Table of DSA, PSA, CE plane, CEAC</td>
      <td class="gt_row gt_left">The total costs and QALYs of each diagnostic strategy were similar, although, incrementally, PCR was the most cost-effective strategy. The analysis does not support routine use of point-of-care tests for either influenza or pneumococcal antigen for adults presenting with acute cardiopulmonary conditions, but suggests that conventional viral culture for clinical diagnosis should be replaced by PCR.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Oppong (2013)</td>
      <td class="gt_row gt_left">€112,7 / antibiotic prescription saved</td>
      <td class="gt_row gt_left">Euros (2007)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">CEAC</td>
      <td class="gt_row gt_left">Patients receiving POCCRP did not have significantly different measures of recovery or outcomes compared to patients not receiving this test.</td>
      <td class="gt_row gt_left">Cost-effective, reduces the rate of antibiotic prescribing.</td>
      <td class="gt_row gt_left">17</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Oppong (2018)</td>
      <td class="gt_row gt_left">Communication skills was associated with an ICER of €68.08 per percentage reduction in antibiotic prescribing when compared with usual care. The ICER for CRP compared with communication skills was €176.53 and the ICER for the combined intervention compared with CRP was €338.89</td>
      <td class="gt_row gt_left">Euros (2016)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">DSA, PSA, CE plane, CEAC</td>
      <td class="gt_row gt_left">In terms of cost per percentage reduction in antibiotic prescribing, overall, communication skills was the most cost-effective intervention. Similarly, the CUA also showed that communication skills was the most cost-effective intervention.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">15</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Pooran (2019)</td>
      <td class="gt_row gt_left">Incremental costs per clinical outcome: diagnosed by index test: 4186; starting treatment: 1464; starting treatment same day: 561; completing treatment: 1211; improved morbidity: 1918</td>
      <td class="gt_row gt_left">US dollars (2014)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Tornado diagram, CEAC</td>
      <td class="gt_row gt_left">Point-of-care Xpert is likely to be cost-effective in settings willing to pay at least $4500 per treatment initiation or $3800 per treatment completion among culture-positive patients</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">14</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Stankiewicz (2003)</td>
      <td class="gt_row gt_left">147 per patient</td>
      <td class="gt_row gt_left">Not reported</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">Not reported</td>
      <td class="gt_row gt_left">With screening CT scanning, patients are diagnosed more accurately, according to whether they have disease or not. This is important because the current subjective method of diagnosis of chronic rhinosinusitis is inaccurate.</td>
      <td class="gt_row gt_left">Cost-saving</td>
      <td class="gt_row gt_left">10</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Van Rie (2013)</td>
      <td class="gt_row gt_left">Cost savings of $3.28 per valid Xpert result</td>
      <td class="gt_row gt_left">US dollars (2010)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">-</td>
      <td class="gt_row gt_left">The cost per Xpert was only US$1.88 higher than the cost for smear microscopy and culture, and US$14.05 higher than smear microscopy only. Due to the low error rate, the cost per valid Xpert result was US$3.28 lower than the cost per valid smear microscopy plus culture result. The cost per case diagnosed was similar for both strategies (US$266 vs. US$260).</td>
      <td class="gt_row gt_left">Cost-saving</td>
      <td class="gt_row gt_left">14</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Wang (2019)</td>
      <td class="gt_row gt_left">Pulmonary: 467.72; extrapulmonary: 291.87 per additional TB diagnosis</td>
      <td class="gt_row gt_left">Not reported</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">Not reported</td>
      <td class="gt_row gt_left">The cost-effectiveness analysis showed that the incremental cost of performing a second Xpert was very high for the smear-positive TB patients</td>
      <td class="gt_row gt_left">Not cost-effective</td>
      <td class="gt_row gt_left">12</td>
    </tr>
    <tr class="gt_group_heading_row">
      <td colspan="8" class="gt_group_heading">Decision trees</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Abimbola (2012)</td>
      <td class="gt_row gt_left">culture: $60,430/death averted; Xpert: dominated</td>
      <td class="gt_row gt_left">US dollars (2010)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Tornado diagram, CEAC</td>
      <td class="gt_row gt_left">A diagnostic approach that includes culture was most effective at averting early deaths, but it was not the least costly approach compared with other algorithms considered. The algorithm with Xpert cost less and was more effective in reducing early mortality compared with the current practice.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Ang (2015)</td>
      <td class="gt_row gt_left">TSt: $3611/QALY; IGRA: dominated; TST and IGRA: 11506/QALY (using TST followed by IGRA as reference)</td>
      <td class="gt_row gt_left">Singapore dollars (2010)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Table of DSA, Tornado diagram, One-way sensitivity analysis, CEAC</td>
      <td class="gt_row gt_left">In the context of our study population, while recognising the difficulties of diagnosing TB uveitis, our results suggest that the dual-test strategy of performing TST and IGRA simultaneously appears to be the most cost-effective strategy relative to the other strategies.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">14</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Behnamfar (2020)</td>
      <td class="gt_row gt_left">RTA + culture: 0.007564; RTA: 0.048541; Culture: 0.049706 (unit: costs /quality-adjusted life day)</td>
      <td class="gt_row gt_left">Not reported</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Tornado diagram</td>
      <td class="gt_row gt_left">The most effective mean observed quality‑adjusted life days was the simultaneous diagnostic treatment of RTA and culture; the highest amount of saving (monetary cost) was detected in RTA before treatment.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">14</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Bertran (2000)</td>
      <td class="gt_row gt_left">Patients with community-acquired pneumonia (CAP): Betalactam antibiotic treatment is the most cost-effective strategy. Hospitalization, directly related to the success rate of the first empirical antibiotic treatment, is the main driver of the final average cost per patient, rating from 50% to 70% of total cost. Acquisition costs of the first empirical antibiotic treatment represents just a small fraction of the total costs (between 2% and 13%)</td>
      <td class="gt_row gt_left">Spanish peseta (1998)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA</td>
      <td class="gt_row gt_left">The model indicates that acquisition costs of the initial empirical antibiotic represent a small fraction of total treatment costs in patients with lower respiratory tract infections acquired in the community</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">9</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Bonnet (2010)</td>
      <td class="gt_row gt_left">B1+B2: €50; D1+B1: €276; : €71; D1+B1+D2, D1+B2, B1+D2, D1+D2+B2, D1+B1+B2, B1+D2+B2: dominated, measure of effectiveness: costs / proportion of smear-positive patients detected among the total number of PTB suspects (using D1+D2 and B1 as references)</td>
      <td class="gt_row gt_left">Euros (2006)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">Table of DSA</td>
      <td class="gt_row gt_left">Considering all potential combinations of direct smear and smear after overnight NaOCl sedimentation, the approaches based on the single examination of the first concentrated specimen or based on the examination of two concentrated specimens were the most cost-effective: B1 due to its low cost, and B1+B2 dueto its effectiveness and low ICER compared to B1.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">14</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Cals (2011)</td>
      <td class="gt_row gt_left">The ICER of GP use of CRP versus usual care was €5.79 and for GP use of both CRP and Communication versus usual care €4.15. Communication was superior to usual care costs or savings /antibiotic prescription saved</td>
      <td class="gt_row gt_left">Euros (Unclear. 2010)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">PSA</td>
      <td class="gt_row gt_left">The interventions are cost-effective in any combination (yielding NMB at no willingness-to pay), taking into account GPs’ preferences where at least 15% of GPs chose to implementthe communication skills training.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">15</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Cowan (2017)</td>
      <td class="gt_row gt_left">XPERT 2 concentrated: $2826682/accurately diagnosed case; 2 smears: $-320893/accurately diagnosed case; 3 smears: $-363987/accurately diagnosed case (reference 1 Xpert concentrated and unconcentrated, which are expected to have equal performance)</td>
      <td class="gt_row gt_left">US dollars (unknown year)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Tornado diagram, Two-way sensitivity analysis, PSA, CE plane, CEAC</td>
      <td class="gt_row gt_left">The present study supports analyses suggesting that Xpert implementation in the United States is cost-effective and can reduce AII duration. .A single-Xpert strategy was cost-saving in a variety of sensitivity analyses, suggesting that replacement of 3 AFB smears with Xpert to determine the need for AII would result in cost savings for most US hospitals.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">15</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">de Bock (2001)</td>
      <td class="gt_row gt_left">Clinical assessment: DFL 515.59; Ultrasound assessment: DFL 5745.38; Radiographic assessment: DFL 3164.98; Antibiotics: DFL 881.67 costs or savings /patient</td>
      <td class="gt_row gt_left">Dutch Florins (year NA)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA, One-way sensitivity analysis, Two-way sensitivity analysis</td>
      <td class="gt_row gt_left">The costs for curing one additional patient were DFL516 when antibiotics were selectively prescribed and DFL882 when antibiotics were prescribed immediately</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">14</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Dugas (2013)</td>
      <td class="gt_row gt_left">PCR: $1389/QALY; treat all: $6246/QALY; treat none: dominated (all compared to provider judgement)</td>
      <td class="gt_row gt_left">US dollars (2011)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Tornado diagram, CEAC</td>
      <td class="gt_row gt_left">Assuming a $50,000 per quality-adjusted life-year willingness-to-pay threshold, the most cost-effective treatment option is treatment according to provider judgment from 0% to 3% prevalence, treatment according to a PCR-based rapid influenza test from 3% to 7% prevalence, and treating all at greater than 7% prevalence.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">18</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Durski (2013)</td>
      <td class="gt_row gt_left">133 per additional correct diagnosis</td>
      <td class="gt_row gt_left">US dollars,  South African Rand (2013)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA</td>
      <td class="gt_row gt_left">Through strategically choosing the order and type of testing coupled with disease prevalence rates, algorithms can deliver more care more efficiently.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Giraldez-Garcia (2011)</td>
      <td class="gt_row gt_left">Only rapid test: 51.22; clinical scoring + rapid test: 50.72 (Costs per patient cured without complications and no adverse reaction to penicillin)</td>
      <td class="gt_row gt_left">Not reported</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">One-way sensitivity analysis, Two-way sensitivity analysis</td>
      <td class="gt_row gt_left">The “clinical scoring + rapid test” strategy was the most cost-effective of the six strategies analysed</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">15</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Gonzalez-Canudas (2011)</td>
      <td class="gt_row gt_left">$12.60 saved each suspected case</td>
      <td class="gt_row gt_left">US dollars (2009)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Fagan nomogram</td>
      <td class="gt_row gt_left">The use of PR as an aid in the diagnosis of H1N1 influenza increases certainty and reduces the average cost per suspect and infected patient.</td>
      <td class="gt_row gt_left">Cost-saving</td>
      <td class="gt_row gt_left">11</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Herráez (2017)</td>
      <td class="gt_row gt_left">€2960/QALY</td>
      <td class="gt_row gt_left">Euros (2016)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Table of DSA, Tornado diagram, PSA, CEAC</td>
      <td class="gt_row gt_left">The implementation of a molecular microbiological technique in the diagnosis of tuberculosisis extremely cost-effective compared to the usual method. Its introduction into the routine diagnostic procedure could lead to an improvement in quality care for patients, given that it would avoid both unnecessary hospitalisations and treatments, and reflected in economic savings to the hospital.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">13</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Holmes (2018)</td>
      <td class="gt_row gt_left">In patients with symptoms of ARTI and based on routine practice, the ICERs of CRP testing were £19,705 per quality-adjusted-life-year (QALY) gained and £16.07 per antibiotic prescription avoided</td>
      <td class="gt_row gt_left">Pound Sterling (2016)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">DSA, Table of DSA, PSA, CE plane, CEAC</td>
      <td class="gt_row gt_left">The model suggests that as implemented in routine primary care (for all adults with symptoms of ARTI for &gt;12 hours where the antibiotic decision unclear) POC CRP testing is borderline cost-effective.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">17</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Lathia (2018)</td>
      <td class="gt_row gt_left">-18.66 (province AB); -14.86 (province BC); -12.78 (province NS); -12.47 (province ON); -24.36 (province SK) costs or savings /patient</td>
      <td class="gt_row gt_left">Not reported</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA</td>
      <td class="gt_row gt_left">This analysis estimates that in a scenario where 60% of patients with severe sore throat seek care in a community pharmacy, compared to a scenario where all patients seek care through a family physician, walk-in clinic or emergency room, the healthcare systems in the five provinces saves a mean of $12.47 to $24.36 per patient.</td>
      <td class="gt_row gt_left">Cost-saving</td>
      <td class="gt_row gt_left">12</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Lavelle (2012)</td>
      <td class="gt_row gt_left">$25,900 to $71,200/QALY, depending on age, compared with the no oseltamivir treatment strategy</td>
      <td class="gt_row gt_left">US dollars (2008)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Table of DSA, One-way sensitivity analysis, CEAC</td>
      <td class="gt_row gt_left">This analysis demonstrates that when seasonal influenza viruses are circulating in the community and antiviral treatment is clinically indicated, empiric oseltamivir treatment of children who are suspected to have influenza illness may be a cost-effective treatment strategy.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">17</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Maizia (2011)</td>
      <td class="gt_row gt_left">970 in children and at 903in adults cost per suppurative complication avoided</td>
      <td class="gt_row gt_left">Euros (2008)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA, Tornado diagram</td>
      <td class="gt_row gt_left">The use of RDT was the most cost-effective strategy from the insurance perspective private US, while the use of culture appeared to be more efficient from the perspective of the system public Medicaid. In acute tonsillitis, in both adults and children, RDT testing by practitioners is the more efficient strategy to identify and treat patients with GAS tonsillitis. Combining RDT testing with throat culture can provide additional effectiveness, but at the cost of a significant extra charge for the community.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">13</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Mewes (2019)</td>
      <td class="gt_row gt_left">The incremental savings per antibiotic day avoided were -$584 for the PCT group</td>
      <td class="gt_row gt_left">US dollars (2017)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">DSA, Tornado diagram</td>
      <td class="gt_row gt_left">Using a Procalcitonin-algorithm to guide antibiotic use in sepsis and hospitalised lower respiratory tract infection patients is expected to generate cost-savings to the hospital and lower rates of antibiotic resistance and C.difficile infections.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Michaelidis (2013)</td>
      <td class="gt_row gt_left">149 / antibiotic prescription saved</td>
      <td class="gt_row gt_left">US dollars (2012)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">PSA, CEAC</td>
      <td class="gt_row gt_left">Procalcitonin testing is unlikely to be preferred over usual care when costs alone are considered, but is likely to be cost-effective when the costs of antibiotic resistance are considered and the test is used only in adults with ARTIs judged to require antibiotics by their physicians.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Nelson (2015)</td>
      <td class="gt_row gt_left">PCR: $115,556/QALY in children aged 3-36 months, and $228,000/QALY in children aged 3-18 yrs (other alternatives were dominated)</td>
      <td class="gt_row gt_left">US dollars (2011)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">One-way sensitivity analysis, CEAC</td>
      <td class="gt_row gt_left">A rapid multiplex PCR strategy was not only the most effective strategy in terms of maximizing patient QALYs, but was also the most expensive.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">15</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Neuner (2003)</td>
      <td class="gt_row gt_left">Culture strategy: 0.2668 quality-adjusted life-day lost and an average cost of $6.66 per patient</td>
      <td class="gt_row gt_left">US dollars (2000)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">DSA, PSA</td>
      <td class="gt_row gt_left">Although the other four strategies had similar effectiveness (all resulted in about 0.27 lost quality-adjusted life-day), culture was the least expensive strategy.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">15</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Oostenbrink (2002)</td>
      <td class="gt_row gt_left">€ 401,965 per QALY (Streptococcus pneumoniae) and €22,635 per QALY (Neisseria meningitidis)</td>
      <td class="gt_row gt_left">Euros (2001)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA</td>
      <td class="gt_row gt_left">Minimizing lumbar punctures and empirical treatments using a diagnostic decision rule, without missing a single case of meningitis, was a dominant strategy to actual practice.</td>
      <td class="gt_row gt_left">Cost-effective, not generalizable for vaccination strategies.</td>
      <td class="gt_row gt_left">17</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Ost (2003)</td>
      <td class="gt_row gt_left">No. of Initial Antibiotics: Zero: Empiric=Na; Empiric + ETT asp=72847; Empiric + mini-BAL=101479; Empiric + FOB=433261; One antibiotic: Empiric=Na; Empiric + ETT asp=20734; Empiric + mini-BAL=86184; Empiric + FOB=634288; Two antibiotics:Empiric + ETT asp=NA; Empiric + mini-BAL=4854; Empiric + FOB=819710; Empiric=dominated; Three antibiotics: Empiric + mini-BAL=NA; Empiric + ETT asp= dominated; Empiric + FOB= 1375978; Empiric= Dominated</td>
      <td class="gt_row gt_left">Not reported</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA, Two-way sensitivity analysis, Three-way (or more) sensitivity analysis graph, PSA</td>
      <td class="gt_row gt_left">From the perspective of minimizing cost, minimizing antibiotic use, and maximizing survival, the best strategy was three antibiotics with mini-BAL.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">14</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Perone (2007)</td>
      <td class="gt_row gt_left">$15.30 (rapid test strategy) per patient</td>
      <td class="gt_row gt_left">Not reported</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA</td>
      <td class="gt_row gt_left">The results of this study is that the rapid test is a valid method for the diagnosis of GABHS. The best clinical strategy for the diagnosis and treatment of pharyngitis in adults is the rapid systematic test in patients with a clinical population greater than or equal to two.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">11</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Pinto (2016)</td>
      <td class="gt_row gt_left">$943 per additional TB diagnosis;  US$356 per additional TB diagnosis with bacteriological confirmation</td>
      <td class="gt_row gt_left">US dollars (2014)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Table of DSA, Tornado diagram, Two-way sensitivity analysis, PSA: uncertainty ranges</td>
      <td class="gt_row gt_left">Xpert is more costly than SSM, but has been shown to be more accurate, and potentially more costeffective in low and high-burden countries with high MDR-TB and HIV co-infection rates. In a setting with low MDR-TB and moderate HIV coinfection rates such as Brazil, implementation of single-sample Xpert testing replacing two-sample SSM tests would result in a modest increase (US$1.2 million per year, or 1.7% of Brazil’s NTP budget) in total health system costs for the additional TB confirmation of 3344 patients.</td>
      <td class="gt_row gt_left">-</td>
      <td class="gt_row gt_left">15</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Rodriguez‐Martinez (2019)</td>
      <td class="gt_row gt_left">"Good practice" was dominant</td>
      <td class="gt_row gt_left">US dollars, Colombian pesos (COP) (2015)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">DSA, Tornado diagram</td>
      <td class="gt_row gt_left">Compared with lack of “good practice,” the utilization of “good practice” in the diagnosis and management of patients with bronchiolitis was associated with both fewer patients readmitted within 10 days of post discharge (0.88 vs 0.99 on average per patient) and lower costs (US$1529.3 versus $1709.1 average cost perpatient), thus leading to dominance</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">14</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Rothberg (2003) - 1</td>
      <td class="gt_row gt_left">All testing strategies are dominated by empiric treatment with amantadine</td>
      <td class="gt_row gt_left">US dollars (2001)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA</td>
      <td class="gt_row gt_left">The economic impact alone validates the use of antiviral therapy in healthy adults with influenza-like illness. The small benefit of shortening symptoms by an average of 1 day is by no means trivial.</td>
      <td class="gt_row gt_left">Cost-saving, Cost-effective</td>
      <td class="gt_row gt_left">15</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Rothberg (2003) - 2</td>
      <td class="gt_row gt_left">Amantadine treatment only: $1129/QALY; test-treat oseltamivir: $5025/QALY, empiric oseltamivir: $10,296/QALY, other test-treat combinations (extended) dominated</td>
      <td class="gt_row gt_left">US dollars (2001)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">One-way sensitivity analysis, Two-way sensitivity analysis, PSA</td>
      <td class="gt_row gt_left">Under most circumstances, antiviral therapy is reasonably cost-effective and within the range of other widely accepted interventions for older adults. The optimal strategy, however, depends on the patient’s vaccination status, the probability that he or she has influenza, and the risk for hospitalization</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">14</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Rothberg (2005)</td>
      <td class="gt_row gt_left">Antiviral therapy: $800 - $1800/QALY; testing stategies were dominated in most scenarios</td>
      <td class="gt_row gt_left">US dollars (2003)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">One-way sensitivity analysis, PSA</td>
      <td class="gt_row gt_left">During local influenza outbreaks, children with symptoms of ILI benefit from antiviral therapy if it is initiated within 48 hours of symptom onset. At the same time, antiviral therapy saves money if parents return to work sooner. In that case, there is no trade-off between cost and effectiveness.</td>
      <td class="gt_row gt_left">Testing not cost-effective - empirical treatment is cost-effective</td>
      <td class="gt_row gt_left">14</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Schuetz (2015)</td>
      <td class="gt_row gt_left">The costs of PCT-guided care for the one million member cohort was $2,083,545, compared to $2,780,332 for the usual care group, resulting in net savings of nearly $700,000 costs or savings /patient</td>
      <td class="gt_row gt_left">US dollars (2014)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA, One-way sensitivity analysis</td>
      <td class="gt_row gt_left">The results show substantial savings associated with the use of PCT to guide antibiotic treatment of ARI in common US treatment settings. Across all three settings PCT-guided care is associated with net savings ranging from $73,326 in the ICU to  &gt; $5 million in the outpatient clinic and ED setting, for total savings to the IDN of more than $6 million.</td>
      <td class="gt_row gt_left">Cost-saving</td>
      <td class="gt_row gt_left">14</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Schwarzinger (2003)</td>
      <td class="gt_row gt_left">test: $-14.40 for 0.65 averted influenza days; empiric treatment: $-29.80 for 0.81 averted influenza day (1)</td>
      <td class="gt_row gt_left">US dollars (1999)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">Table of DSA, One-way sensitivity analysis</td>
      <td class="gt_row gt_left">During influenza epidemics, when unvaccinated healthy working adults consult within 2 days of the onset of influenza-like symptoms, systematic zanamivir prescription without rapid influenza test is a dominant strategy from a societal perspective.</td>
      <td class="gt_row gt_left">Cost-saving</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Shah (2013)</td>
      <td class="gt_row gt_left">ZN microscopy + urine sample testing: $33/DALY; Xpert on one sputum: $58/DALY; Xpert on one sputum + urine sample testing: $57/DALY (ZN microscopy as reference)</td>
      <td class="gt_row gt_left">US dollars (2013)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">One-way sensitivity analysis, CEAC</td>
      <td class="gt_row gt_left">Compared with an algorithm of Xpert testing alone, the combination of Xpert with LFLAM was considered highly cost-effective. Addition of urine LF-LAM testing to smear-microscopy was a less effective strategy than Xpert replacement of smear-microscopy, but was less costly and also considered highly cost-effective compared with continued usage of smear-microscopy alone.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Shen (2016)</td>
      <td class="gt_row gt_left">32,810/QALY</td>
      <td class="gt_row gt_left">Chinese yuan (no year)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">Tornado diagram, cost-effectiveness plane</td>
      <td class="gt_row gt_left">The empiric oseltamivir treatment of children who are suspected to have influenza illness may be a dominant or a very cost-effective treatment strategy in comparison against post RIDT treatment with oseltamivir and no antiviral therapy.</td>
      <td class="gt_row gt_left">Not cost-effective</td>
      <td class="gt_row gt_left">13</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Siddiqui (2008)</td>
      <td class="gt_row gt_left">For stockpiling: ₤1900 and ₤13700/QALY for the 1918 and 1957/69 scenarios; test-treat ₤31000 and ₤228000/QALY</td>
      <td class="gt_row gt_left">Pound Sterling (2004)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Tornado diagram, One-way sensitivity analysis, cost-effectiveness plane</td>
      <td class="gt_row gt_left">Near-patient testing is unlikely to be a cost-effective approach to conserving AV stocks but might be considered early in a pandemic. A more cost-effectivestrategy would be to increase the stockpile of AV drugs.</td>
      <td class="gt_row gt_left">Not cost-effective</td>
      <td class="gt_row gt_left">14</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Smith (2002)</td>
      <td class="gt_row gt_left">Empiric amantadine: $9.06 per illness day avoided; empiric oseltamivir: $198 per illness day avoided; other strategies (extended) dominated</td>
      <td class="gt_row gt_left">US dollars (2000)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Tornado diagram, CEAC</td>
      <td class="gt_row gt_left">Amantadine, zanamivir, and oseltamivir cost about $250 or less per quality-adjusted day gained or illness day avoided for patients with fever and typical influenza symptoms. Rapid testing was, forthe most part, more costly and less effective than treatment without testing.</td>
      <td class="gt_row gt_left">"Economically reasonable"</td>
      <td class="gt_row gt_left">12</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Stojanovic (2017)</td>
      <td class="gt_row gt_left">In the inpatient setting, the costs of PCT-guided care compared to usual care resulted in net savings of 721,563 CNY Chinese hospital system; In the ICU and outpatient settings, savings were 250,699 CNY and 2.4 million CNY, respectively. The overall annual net savings of PCT-guided care was nearly 3.4 million CNY</td>
      <td class="gt_row gt_left">Chinese yuan (2015)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA</td>
      <td class="gt_row gt_left">Our results demonstrate substantial savings associated with the use of PCT to guide antibiotic treatment of ARI across common China treatment settings.</td>
      <td class="gt_row gt_left">Cost-saving</td>
      <td class="gt_row gt_left">17</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Takwoingi (2019)</td>
      <td class="gt_row gt_left">Varying from 6640 to 22010 /QALY</td>
      <td class="gt_row gt_left">Not reported</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">CE plane, CEAC</td>
      <td class="gt_row gt_left">The use of current IGRA tests for ruling out active TB would be unlikely to be considered cost-effective if a QALY were to be valued at £20,000 or £30,000. There are cost savings, but the health detriment is large because of the delay in diagnosing active TB.</td>
      <td class="gt_row gt_left">Not cost-effective</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Tillekeratne (2019)</td>
      <td class="gt_row gt_left">The incremental cost per antibiotic prescription avoided with clinical prediction versus standard care was US$3.0, which was lower than the base-case estimate of the cost of antimicrobial resistance per ILI antibiotic prescription (US$12.5)</td>
      <td class="gt_row gt_left">US dollars (2014)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">DSA, PSA</td>
      <td class="gt_row gt_left">Standard care was less expensive than other strategies across all parameter values in one-way sensitivity analyses. To obtain a cost-effectiveness ratio lower than US$12.5 with targeted testing versus standard care, the test price must be &lt;US$2.6. At a higher threshold of US$28.7, the test price must be &lt;US$7.7.</td>
      <td class="gt_row gt_left">Cost-saving</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Van Howe (2006)</td>
      <td class="gt_row gt_left">$32,132.01 rapid antigen testing had the best cost-utility. It dominated both "treat all" and "rapid test + culture" strategies</td>
      <td class="gt_row gt_left">US dollars (2003)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Table of DSA, Tornado diagram, PSA</td>
      <td class="gt_row gt_left">When the cost of a culture is low, in comparison with a paid test, culturing samples for all children may be the best option. As the cost of throat cultures increase, relative to the price of a rapid test, the rapid test becomes the better option.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">15</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Vassall (2011)</td>
      <td class="gt_row gt_left">Xpert after two negative smear examinations: India: $55/DALY, South Africa: $110/DALY, Uganda: $41/DALY; Xpert instead of smear examination: India: $68/DALY, South Africa: $138/DALY, Uganda: $37/DALY</td>
      <td class="gt_row gt_left">US dollars (2010)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Table of DSA, One-way sensitivity analysis, Three-way  sensitivity analysis graph, CEAC</td>
      <td class="gt_row gt_left">Our results suggest that Xpert is likely to be more cost-effective than a base case of smear microscopy and clinical diagnosis of smear-negative TB.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Walusimbi (2016)</td>
      <td class="gt_row gt_left">MODS: $34 per TB patient diagnosed; Xpert: $71 per TB patient diagnosed</td>
      <td class="gt_row gt_left">US dollars (2014)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">Table of DSA, Tornado diagram</td>
      <td class="gt_row gt_left">The algorithm using MODS was more cost-effective compared to the algorithm using Xpert for a wide range of different values of accuracy, cost and TB prevalence. The cost (threshold value), where the algorithm using Xpert was optimal over the algorithm using MODS was $5.92</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Xie (2017)</td>
      <td class="gt_row gt_left">Incremental cost per patient 36 dollars. Incremental costs per case correctly classified 582 dollars</td>
      <td class="gt_row gt_left">Canadian dollars (year unknown)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">DSA</td>
      <td class="gt_row gt_left">An overall increase in diagnostic accuracy of 6.2% due to the addition of BinaxNOW‐SP.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">13</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">You (2012)</td>
      <td class="gt_row gt_left">Empirical treatment dominates testing</td>
      <td class="gt_row gt_left">US dollars (2011)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Two-way sensitivity analysis, CEAC</td>
      <td class="gt_row gt_left">In a season when the ‘seasonal influenza’ virus strains are predominant, ‘‘empirical antiviral treatment alone’’ would be a cost-effective option at influenza prevalence levels of 2.5% or above, whereas the ‘PCR guided treatment’ approach would be cost-effective at a low prevalence of less than 2.5%.</td>
      <td class="gt_row gt_left">Not cost-effective</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">You (2015)</td>
      <td class="gt_row gt_left">$99/QALY</td>
      <td class="gt_row gt_left">US dollars (2014)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">One-way sensitivity analysis, CEAC</td>
      <td class="gt_row gt_left">Using a simple sputum test of Xpert at inital assessment was the most cost-effective option</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">12</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">You (2017)</td>
      <td class="gt_row gt_left">$29582/QALY</td>
      <td class="gt_row gt_left">US dollars (2017)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Table of DSA, Tornado diagram, cost-effectiveness plane, CEAC</td>
      <td class="gt_row gt_left">The expected ICER of POCT-PCR is SD29,582, lower than 1x GDP per capita of Hong Kong (USD43,497). The base-case ICER is therefore highly cost-effective from the perspective of healthcare provider in Hong Kong.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">15</td>
    </tr>
    <tr class="gt_group_heading_row">
      <td colspan="8" class="gt_group_heading">Markov models</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Balk (2001)</td>
      <td class="gt_row gt_left">34.0 costs/symptom free day (in a mild scenario)</td>
      <td class="gt_row gt_left">US dollars (year NA)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA, Table of DSA, One-way sensitivity analysis</td>
      <td class="gt_row gt_left">The best strategy for diagnosing and treating acute sinusitis depends in part on the prevalence of the bacterial sinusitis (or the likelihood that a given patient actually has the disease)</td>
      <td class="gt_row gt_left">Cost-saving, Cost-effective</td>
      <td class="gt_row gt_left">15</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Hunter (2015)</td>
      <td class="gt_row gt_left">The two strategies result in 0.13 additional QALYs per 100 patients and costs 42 pounds less per 100 patients  for the GP plus CRP strategy and 680 pounds less for the nurse plus CRP strategy</td>
      <td class="gt_row gt_left">Pound Sterling (2012)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA, PSA, CE plane, CEAC</td>
      <td class="gt_row gt_left">Over a 3-year time horizon, GP plus CRP test and nurse plus CRP test have a higher net monetary benefits than current practice. The additional costs of the test is outwighted by cost savings and QALY increment associated with a reduction in infections in the long run.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">18</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Wikman (2017)</td>
      <td class="gt_row gt_left">SM + MODS: $5648/DALY;  MODS: $5375/DALY; SM + Xpert: $346/DALY; Xpert: $122/DALY</td>
      <td class="gt_row gt_left">US dollars (2013)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Tornado diagram, PSA, CE plane</td>
      <td class="gt_row gt_left">Our results suggest that in this rural African setting substituting SM by Xpert MTB/RIF would be the most cost-effective strategy compared to its implementation as an add-on strategy or MODS implementation. However, the degree of uncertainty is high.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">15</td>
    </tr>
    <tr class="gt_group_heading_row">
      <td colspan="8" class="gt_group_heading">Dynamic models</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Mears (2016)</td>
      <td class="gt_row gt_left">₤95,628/QALY (LTBI detecting increase from 3% to 4%); ₤54,539/QALY (LTBI detecting increase from 3% to 13%); cost-saving if diagnostic delay was reduced with 1 week</td>
      <td class="gt_row gt_left">Pound sterling (unknown year)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">Table of DSA, One-way sensitivity analysis</td>
      <td class="gt_row gt_left">This analysis failed to demonstrate that the TB-STS is a cost-effective use of NHS resources. It suggests that it is unlikely that earlier identification of false positive cases related to laboratory contamination, or increases in the identification and prophylactic treatment of contacts with a latent infection could, on their own, justify the cost of the system.</td>
      <td class="gt_row gt_left">Not cost-effective</td>
      <td class="gt_row gt_left">17</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Menzies (2012)</td>
      <td class="gt_row gt_left">$784/DALY; $810/life-year saved</td>
      <td class="gt_row gt_left">US dollars (2011)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Table of DSA, Tornado diagram, Three-way sensitivity analysis graph, CEAC, uncertainty interval (2.5 and 97.5 percentiles)</td>
      <td class="gt_row gt_left">Along with the projected health benefits of scaling up Xpert will come significantly increased demands on healthcare resources. The large increase in funding required under the Xpert scenario raises the question of affordability. Although our cost-effectiveness results suggest that the introduction of Xpert represents good value for money according to typical international benchmarks, it does not automatically follow that TB program budgets will be able toabsorb these changes.</td>
      <td class="gt_row gt_left">-</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr class="gt_group_heading_row">
      <td colspan="8" class="gt_empty_group_heading"></td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Harris (2011)</td>
      <td class="gt_row gt_left">At 50% disease prevalence, diagnostic procedures involving expectorated sputum with any PCR method, or induced sputum with nested or real-time PCR, were all highly cost-effective, successfully treating 77–90% of patients at $26–51 per life-year gained.</td>
      <td class="gt_row gt_left">Not reported</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA</td>
      <td class="gt_row gt_left">Three metrics are relevant: proportion of PCP patients successfully treated, proportion of well persons unnecessarily treated, and the total diagnostic and treatment cost per life-year gained.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">15</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Jha (2016)</td>
      <td class="gt_row gt_left">Main outcome reported: $1280 per incremental TB diagnosis, TBDx automated microscopy</td>
      <td class="gt_row gt_left">US dollars (2015)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Table of DSA, Tornado diagram, Uncertainty ranges (95%) around results</td>
      <td class="gt_row gt_left">In settings where universal XpertMTB/RIF is affordable, and health systems are willing to pay at least $1927 per incremental TB diagnosis made, universal Xpert is generally preferred.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">14</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Langley (2014)</td>
      <td class="gt_row gt_left">LED microscopy: $29/DALY; same-day LED microscopy: $45/DALY; full Xpert: $169/DALY; others dominated</td>
      <td class="gt_row gt_left">US dollars (2011)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Table of DSA, Tornado diagram, PSA, CEAC, 95% credible intervals</td>
      <td class="gt_row gt_left">We have assessed the effect of several promising tuberculosis diagnostic options that are being considered by many national tuberculosis programmes, and have identified three cost-effective strategies in the context of Tanzania: full rollout of Xpert MTB/RIF (B1), followed by same-day LED fluorescence microscopy (A3) and LED fluorescence microscopy(A2).</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">17</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Lee (2019)</td>
      <td class="gt_row gt_left">Truenat POC: 210 /LYG, which dominated all other strategies</td>
      <td class="gt_row gt_left">US dollars (2017)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">DSA, Two-way sensitivity analysis</td>
      <td class="gt_row gt_left">Truenat, when replacing smear microscopy and used at point-of-care, increases the number of TB cases correctly detected and linked to care by 590 per 10,000 individuals with presumptive TB. It also increases life expectancy by nearly 0.4 years and is cost-effective</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">17</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Naidoo (2016)</td>
      <td class="gt_row gt_left">$6274 per additional MDR-TB case diagnosed</td>
      <td class="gt_row gt_left">US dollars (2013)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">-</td>
      <td class="gt_row gt_left">The introduction of the Xpert-based algorithm has resulted in substantial increases in cost which are in line with modelling exercises undertaken in South Africa. However these were not matched by an increase in TB diagnostic efficacy; massive cost increases persist even when temporal trends of a possible declining TB prevalence were taken into consideration. One of the benefits of the Xpert-based algorithm was the modest increase in the number of MDR-TB cases diagnosed, which comes at high cost.</td>
      <td class="gt_row gt_left">-</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Nshimyumukiza (2016)</td>
      <td class="gt_row gt_left">$7573 saved /100,000 person years and 1.92 life-years saved /100,000 person years</td>
      <td class="gt_row gt_left">Canadian dollars (2011-2012)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">Tornado diagram, CEAC</td>
      <td class="gt_row gt_left">Considering the baseline values of sensitivity, specificity, and cost to be 74%, 99%, and $25, respectively, for a POC test; the antiviral treatment based on this test appears dominant as compared to empirical antiviral treatment based on clinical judgment.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Oostenbrink (2003)</td>
      <td class="gt_row gt_left">Total costs current practice €2.976; total costs decision rule €2.684</td>
      <td class="gt_row gt_left">Euros (2001)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA</td>
      <td class="gt_row gt_left">The decision rule reduced total costs by 292 euros per patient, 33 euros in the diagnostic phase and 259 euros in the treatment course.The application of the decision rule reduced the number of patients hospitalized.</td>
      <td class="gt_row gt_left">Cost-saving</td>
      <td class="gt_row gt_left">14</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Sohn (2019)</td>
      <td class="gt_row gt_left">3161 /DALY</td>
      <td class="gt_row gt_left">US dollars (2015)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">One-way sensitivity analysis, CEAC</td>
      <td class="gt_row gt_left">Provided that decentralized testing can be performed with equal quality as centralized testing, the costs and LTFU incurred by using a hub-and-spoke system are likely to justify the increased costs of decentralized testing, except in settings where testing volumes is low.</td>
      <td class="gt_row gt_left">Not clear</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Suen (2015)</td>
      <td class="gt_row gt_left">PPM: $72/QALY; PPM + Xpert: 145/QALY; PPM + Xpert in public clinics: 1104/QALY (others dominated)</td>
      <td class="gt_row gt_left">US dollars (2013)</td>
      <td class="gt_row gt_left">Yes</td>
      <td class="gt_row gt_left">CEAC, partly PSA (on the simultaneous effect of uncertainty about the quality of life lost due to TB and the costs of care)</td>
      <td class="gt_row gt_left">Our results illustrate that there is no silver bullet for combating the TB epidemic -- introducing rapid and accurate diagnostic systems, either for initial diagnosis or DST, will have limited ability to control the epidemic and, in a context where PPM is available, is not cost-effective if implemented without substantial effort to bring the fragmented public and private treatment systems together.</td>
      <td class="gt_row gt_left">Cost-effective</td>
      <td class="gt_row gt_left">16</td>
    </tr>
    <tr>
      <td class="gt_row gt_left">Yakhelef (2014)</td>
      <td class="gt_row gt_left">Varying between €452-€3121 per case depending on exact algoritm used</td>
      <td class="gt_row gt_left">Euros (2009)</td>
      <td class="gt_row gt_left">No</td>
      <td class="gt_row gt_left">DSA</td>
      <td class="gt_row gt_left">Using TLA/LJ in addition to the conventional algorithm made it more expensive, although its cost-effectiveness would improve if the number of screened patients increased. The decision to adopt rapid culture for TB epends on the government/community’s willingness to pay for it.</td>
      <td class="gt_row gt_left">culture-based algorithm may be hard to afford for resource-limited countries</td>
      <td class="gt_row gt_left">15</td>
    </tr>
  </tbody>
  <tfoot class="gt_sourcenotes">
    <tr>
      <td class="gt_sourcenote" colspan="8">CE: Cost Effectiveness; CEAC: Cost-Effectiveness Acceptability Curve; DALY: Disability-Adjusted Life Year; DSA: Deterministic Sensitivity Analysis; PSA: Probabilistic Sensitivity Analysis; QALY: Quality-Adjusted Life Year</td>
    </tr>
  </tfoot>
  
</table></div>
</body>
</html>
